Format

Send to

Choose Destination
Cancer Res. 2014 Sep 1;74(17):4845-4852. doi: 10.1158/0008-5472.CAN-14-1232-T. Epub 2014 Jul 23.

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

Author information

1
Department of Genomic Medicine The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
2
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
3
Department of Cancer Biology The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
4
Department of Systems Biology The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
5
Department of Dermatology The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
6
Department of Melanoma Medical Oncology The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
7
Institute for Applied Cancer Science The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
#
Contributed equally

Abstract

Following mutations in BRAF and NRAS, the RAC1 c.85C>T single-nucleotide variant (SNV) encoding P29S amino acid change represents the next most frequently observed protein-coding hotspot mutation in melanoma. However, the biologic and clinical significance of the RAC1 P29S somatic mutation in approximately 4% to 9% of patients remains unclear. Here, we demonstrate that melanoma cell lines possessing the RAC1 hotspot variant are resistant to RAF inhibitors (vemurafenib and dabrafenib). Enforced expression of RAC1 P29S in sensitive BRAF-mutant melanoma cell lines confers resistance manifested by increased viability, decreased apoptosis, and enhanced tumor growth in vivo upon treatment with RAF inhibitors. Conversely, RNAi-mediated silencing of endogenous RAC1 P29S in a melanoma cell line with a co-occurring BRAF V600 mutation increased sensitivity to vemurafenib and dabrafenib. Our results suggest RAC1 P29S status may offer a predictive biomarker for RAF inhibitor resistance in melanoma patients, where it should be evaluated clinically.

PMID:
25056119
PMCID:
PMC4167745
DOI:
10.1158/0008-5472.CAN-14-1232-T
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center